Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has earned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $12.2308.

CMPX has been the topic of several analyst reports. Lifesci Capital assumed coverage on Compass Therapeutics in a research note on Monday, October 6th. They issued an “outperform” rating and a $10.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. William Blair started coverage on shares of Compass Therapeutics in a research report on Monday, January 5th. They issued an “outperform” rating on the stock. Leerink Partners raised shares of Compass Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 26th. Finally, Citizens Jmp initiated coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 target price for the company.

Compass Therapeutics Stock Up 0.3%

Shares of NASDAQ CMPX opened at $6.40 on Tuesday. Compass Therapeutics has a 12-month low of $1.33 and a 12-month high of $6.49. The firm’s 50-day simple moving average is $5.46 and its 200 day simple moving average is $4.27. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -14.22 and a beta of 1.45.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. On average, equities analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CMPX. Suvretta Capital Management LLC raised its holdings in shares of Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after purchasing an additional 6,951,666 shares during the last quarter. Vivo Capital LLC increased its stake in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in Compass Therapeutics during the 3rd quarter worth about $9,892,000. Millennium Management LLC lifted its position in Compass Therapeutics by 280.4% during the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after buying an additional 2,386,367 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after buying an additional 2,212,794 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.